Article Text

Download PDFPDF
Feasibility Study of Adjuvant Chemotherapy Using Taxane Plus Carboplatin for High-Risk Patients With Uterine Cervical Non-Squamous Cell Carcinoma After Radical Hysterectomy
  1. Seiya Sato, MD, PhD*,
  2. Muneaki Shimada, MD, PhD*,
  3. Tsuyoshi Ohta, MD, PhD,
  4. Takanobu Kojimahara, MD, PhD,
  5. Hideki Tokunaga, MD, PhD,
  6. Tadao Takano, MD, PhD,
  7. Satoshi Yamaguchi, MD, PhD§,
  8. Hiroshi Tanabe, MD, PhD,
  9. Shin Nishio, MD, PhD and
  10. Junzo Kigawa, MD, PhD#
  1. *Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago City;
  2. Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, Yamagata;
  3. Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai;
  4. §Department of Gynecologic Oncology, Hyogo Cancer Center, Akashi;
  5. Department of Obstetrics and Gynecology, Jikei University School of Medicine, Minato;
  6. Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume; and
  7. #Department of Obstetrics and Gynecology, Matsue City Hospital, Matsue, Japan.
  1. Address correspondence and reprint requests to Muneaki Shimada, MD, PhD, Department of Obstetrics and Gynecology, Tottori University School of Medicine, 36-1 Nishicho, Yonago City 683-8504, Japan. E-mail: mshima12@med.tottori-u.ac.jp.

Abstract

Objective We conducted this study to evaluate the efficacy and safety of adjuvant chemotherapy using taxane plus carboplatin (CBDCA) for high-risk stage IB–IIB patients with uterine cervical non-squamous cell carcinoma after radical hysterectomy.

Methods Thirty-seven patients were eligible. Pelvic lymph node involvement and/or parametrial invasion were defined as high-risk factors. The patients were treated with 6 cycles of paclitaxel (PTX, 175 mg/m2) or docetaxel (DTX, 60 mg/m2) followed by CBDCA (area under the curve, 6) every 3 weeks. The primary end point was 2-year progression-free survival (PFS) rate, and the secondary end point was the assessment of adverse events.

Results Twenty-two patients received PTX/CBDCA (TC) chemotherapy, and the remaining 15 patients underwent DTX/CBDCA (DC) chemotherapy. The 2-year PFS rate was 62.1% (95% confidence interval, 44.6%–75.5%). Patients receiving DC chemotherapy showed a better 2-year PFS rate compared to those with TC chemotherapy, but the difference was not statistically significant (80.0% vs 50.0%, P = 0.1400). The most common grade 3/4 adverse events were hematologic toxicities, which were generally well tolerable. Nonhematologic toxicity was generally mild.

Conclusions Taxane and CBDCA combination chemotherapy, especially DC chemotherapy, may be one of the useful adjuvant treatments for high-risk stage IB–IIB patients with uterine cervical non-squamous cell carcinoma after radical hysterectomy.

  • Cervical cancer
  • Non-squamous cell carcinoma
  • Adjuvant chemotherapy

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.